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A preponderance of patients with neuroendocrine tumors (NETs) will experience hepatic metastases during the course of their
disease. Many diagnoses of NETs are made only after the neoplasms have spread from their primary gastroenteropancreatic sites
to the liver. This paper reviews current evidence-based treatments for neuroendocrine hepatic metastases, encompassing surgery,
hepatic artery embolization (HAE) and chemoembolization (HACE), radioembolization, hepatic artery infusion (HAI), thermal
ablation (radiofrequency, microwave, and cryoablation), alcohol ablation, and liver transplantation as therapeutic modalities.
Consideration of a multidisciplinary approach to liver-directed therapy is strongly encouraged to limit morbidity and mortality in
this patient population.
1.Introduction
Once considered extremely rare, neuroendocrine tumors
(NETs), which include carcinoid tumors and pancreatic islet
cell tumors, are increasing in incidence [1]a n dp r e v a l e n c e
and likely remain underdiagnosed [2]. The disease course of
these tumors is far from universally indolent, and metastatic
involvement of the liver typically represents the greatest
threat of morbidity and mortality posed by these malignan-
cies. Regardless of their site of origin in the intestine, pan-
creas, or elsewhere, neuroendocrine carcinomas can com-
promise normal hepatic function when they spread to the
liver parenchyma. Furthermore, midgut carcinoids, whose
secretory peptides would ordinarily have been inactivated
through enterohepatic circulation, can circumvent this ﬁrst-
pass clearance and then release vasoactive amines into sys-
temic bloodﬂow, causing the carcinoid syndrome [3].
Pathologically, neuroendocrine carcinomas constitute a
substantial fraction of noncolorectal metastases to the liver
[4], and some of the techniques honed during management
of oligometastatic colorectal disease have been applied to
NETs. Survival after NETs metastasize to the liver is usually
longer than the median survival times encountered in stage
IV colon or rectal cancer and thus may provide a wider win-
dow of opportunity for intervention. However, the unique
biologyofNETsmeansthattheprinciplesappliedtocolorec-
talmetastasescannotbefullyextrapolatedtomanagementof
this less common tumor type. For instance, neuroendocrine
metastases tend to be more numerous and hypervascular,
which may aﬀect surgical decision making and lower the
thresholdforablativeapproachesbyinterventionalradiology
[5].
2. Surgery
Surgery remains the treatment of choice. Neuroendocrine
metastases are often well circumscribed and are less likely
to encase or invade vascular and biliary structures than
other malignancies which spread to the liver parenchyma,
generally improving their resectability as a histologic group
[5].Theaimofhepaticmetastasectomyisremovalofallgross
tumor [6], but it is important to attempt cytoreduction, if
feasible, even when total resection is not possible [7]. In the
past, bilobar involvement or concerns about high recurrence
rates meant many patients were not oﬀered excisions of2 International Journal of Hepatology
their metastases. However, increasing experience with more
extensive surgeries and the coupling of aggressive resections
to favorable outcomes have expanded the modern criteria of
operative eligibility [8].
Radiographic evaluation of the liver is mandatory for ap-
propriate surgical planning. Although miliary dissemination
of disease throughout the liver was considered unusual in the
past [9], it is far from uncommon to encounter metastases of
varying sizes in both hepatic lobes, and preoperative imaging
and postoperative pathologic analysis alike can miss small
lesions if the liver is not examined in suﬃciently thin slices.
An important study by Dromain and colleagues compared
the relative sensitivities of MRI, CT, and somatostatin recep-
tor scintigraphy (SRS, coupled to single-photon emission
coupled CT) in detecting well-diﬀerentiated neuroendocrine
metastases to the liver. 64 patients underwent each of these
3 imaging modalities in random sequence preprocedurally,
and the pathology yielded by either liver biopsy or surgery
was then compared to the radiographic ﬁndings. MRI de-
tected 190 hepatic metastases missed by SRS and 69 missed
by spiral CT. As such, liver MRI was recommended as the
single most useful imaging modality in assessing the hepatic
metastatic burden from NETs [10].
At least half of NET patients will have more than 50% of
their liver replaced at the time metastases are ﬁrst recognized
[11], but the percentage of involvement of the hepatic
parenchyma by tumor does not necessarily aﬀect surgical
outcome [12]. The resection of more than three segments
of the liver is necessary in the majority of cases [13], with
a goal of debulking 90% or more of the appreciable tumor
burden [14]. In a retrospective univariate outcomes analysis
by Saxena et al., of 40 patients undergoing concomitant
resection and cryoablation, resection of 3 or more liver
segments predicted for a poorer progression-free survival,
but there was no diﬀerence in overall survival based on the
numberofsegmentsresected[15].Inaseparateretrospective
single-institution series described by Saxena et al. of 74
patients undergoing resection of neuroendocrine metastases
(of whom 38 underwent simultaneous cryotherapy), median
postresection progression-free and overall survivals were
reportedat23and95months,respectively,with40%postop-
erative 10-year survival; high histologic grade and extrahep-
aticdiseaseweresigniﬁcantlyassociatedwithshortersurvival
[16]. 33 of the patients had their tumor necrosis status
recorded as a binary variable; 9 of the 33 cases demonstrated
tumornecrosis,whichwassigniﬁcantlyassociated(P = .047)
with poorer overall survival in univariate analysis. Suggested
operative selection criteria (Table 1) thus include little to
no extrahepatic disease, no indication of tumor necrosis,
and well-diﬀerentiated (versus poorly diﬀerentiated) disease
[15].
Operative planning must address the possibility of dis-
tant, nonprimary disease at the time when liver metastases
are diagnosed. Among the available imaging modalities,
octreotide scintigraphy may have the greatest utility in de-
tectingorexcludingextrahepaticdisease[17].Thistechnique
relies upon the binding of radiolabeled octreotide to the
somatostatinreceptor(especiallysubtype2)expressedonthe
surface of the NETs in order to make tumors conspicuous
Table 1: Suggested eligibility criteria for resection of NET liver
metastases.
No miliary disease on preoperative liver imaging
(MRI or multidetector CT)
Little to no extrahepatic disease on preoperative nuclear medicine
studies
(18FF-DOPA PET preferred over octreotide scintigraphy for carcin-
oid)
Well- or moderately diﬀerentiated neuroendocrine carcinoma
(Ki-67 <20% and ideally, <15%)
Projected volume of residual functional liver >30%
No tumor necrosis
during the nuclear medicine study. Pitfalls of this approach
include high background uptake of the radioligand by abdo-
minal organs, for example, the spleen, liver, kidneys, and
gut lymphoid tissue, as well as variable tumor diﬀerentiation
and receptor expression aﬀecting homogenous binding of
the octreotide at the site of disease [18]. There is also a
lower limit of detection based upon tumor size, such that
the radiolabeling most reliably highlights lesions at least
1cm in diameter, so scintigraphy remains mostly adjunctive
to other modes of disease visualization and is now seldom
used without correlation to higher-resolution cross-sectional
imaging [19]. A study by Montravers et al. of 30 French
patients with well-diﬀerentiated NETs in the digestive tract
suggested that histology should be factored into the selec-
tion of the optimal nuclear imaging modality. While they
found that (111)In-pentetreotide scintigraphy did not dif-
ferentially detect carcinoid versus noncarcinoid tumors (as
deﬁned by the 2000 WHO classiﬁcation of NETs [20]),
18F-ﬂuorodihydroxyphenylalanine (18FF-FDOPA) PET had
a higher detection rate of carcinoid tumors, leading the
authors to recommend PET over scintigraphy in the clinical
contexts of detecting the primary carcinoid tumor, stag-
ing/restaging, and identifying otherwise-occult recurrences
[21].Focusingontheliveritself,Becheneretal.examinedthe
relative utility of PET versus scintigraphy in assessing hepatic
disease burden from both carcinoid and noncarcinoid NETs.
In 17 patients later proven to have liver metastases, the
sensitivity of 18F-FDOPA PET was 81.3% versus 75% with
scintigraphy, oﬀering only a fractional beneﬁt for the pur-
poses of surgical planning. Moreover, the speciﬁcity of PET
was lower than scintigraphy (85.7% versus 100%, resp.) due
to false-positive hypermetabolism at the site of a metastatic
lesion that had previously been embolized [22].
Carcinomatosis is a form of extrahepatic disease that can
be particularly diﬃcult to discern preoperatively, as tumor
nodules usually have to be >1 c mi ns i z et ob er e l i a b l y
discernible on MRI, CT, or octreotide scintigraphy. Fur-
thermore, the abdominal discomfort related to peritoneal
involvement can be highly nonspeciﬁc and indistinguishable
byhistoryfrompainrelatedtotheprimarytumor.Ascitesisa
ﬁnding that raises the index of suspicion for carcinomatosis,
but negative ascitic ﬂuid cytology does not rule out peri-
toneal involvement. Minimally invasive staging laparoscopy
can be particularly helpful in such cases and also allow visualInternational Journal of Hepatology 3
inspection of liver surfaces, adding to the assessment of the
hepatic disease burden [23]. It should be noted that con-
current carcinomatosis is not an absolute exclusion criterion
when considering patients for hepatic metastasectomy. In a
multicenter French study, among 116 consecutive patients
seen for digestive endocrine tumors, Vasseur et al. identiﬁed
9 patients with both liver metastases and peritoneal carcino-
matosis; of the 5 deaths that occurred during their followup,
4 were related to the progression of liver metastases, and no
death resulted from the peritoneal carcinomatosis. As such,
the authors concluded (admittedly on the basis of a small
sample size) that the presence versus absence of peritoneal
involvement by the neuroendocrine malignancy did not
aﬀect survival, and that carcinomatosis should not detract
from eﬀorts to control more life-threatening liver involve-
ment [24].
If there is concern that resection will result in insuﬃcient
residual liver volume, that is, <30% functional liver, portal
vein embolization (PVE) can be performed about a month
before surgery to induce hypertrophy of the parenchyma
that will constitute the postoperative hepatic remnant [25].
Embolization of the right portal vein, for instance, can in-
duce enlargement of the left hepatic lobe in cases where right
hepatectomy is planned, especially if local ablative therapies
will also be applied in the left lobe. The coupling of ablation
(described in more detail below) to extended liver resection
(±PVE) has expanded the eligibility of patients with bilobar
disease to receive directed cytoreductive therapy.
In addition to preoperative imaging, closely evaluating
the histologic characteristics of the NET constitutes an im-
portant step in surgical decision making. Tumor diﬀeren-
tiation and the Ki-67 proliferative index are independent
prognostic factors of survival and may inﬂuence the decision
to pursue an operation. In a single-institution study of 63
consecutive patients presenting with NETs metastatic to the
liver, Hentic et al. reported that the 18 patients with poorly
diﬀerentiated NETs had a 5-year survival of 6%, markedly
inferior to the respective 89% and 36% 5-year survival rates
in cases of well-diﬀerentiated NETs with <15% and ≥15%
Ki-67 indices. The median survival of the poorly diﬀeren-
tiated cohort (who, by deﬁnition, had Ki-67 >20%) was 14
months, and only 1 of these 18 patients underwent resection
(versus 15 of the 45 patients with well-diﬀerentiated NETs
who proceeded to surgery). The authors concluded that,
among their patients with well-diﬀerentiated NETs, Ki-67
carried more prognostic importance than the extent of
liver involvement and postulated that an aggressive surgical
approach likely explained the favorable survival rates in this
cohort [26].
Although overall survival from NETs appears to worsen
with hormonally active tumors versus their nonfunctional
counterparts [1], survival after hepatic metastasectomy does
not diﬀer between functional and nonfunctional tumors [8].
While echocardiography is obviously an important compo-
nent of preoperative assessment for carcinoid patients [27],
it has been shown that even patients who have already pro-
gressed to carcinoid heart disease have slower declines in car-
diac function and prolonged survival after resection of their
hepaticmetastases,sothissubgroupshouldnotbereﬂexively
excluded from surgical consideration [28] (although peri-
operative consultation with cardiology is strongly advised).
Indeed, NET patients with endocrinopathies may stand
to experience greater symptomatic beneﬁt and improved
quality of life after their operations.
Outcome data from several trials examining neuroen-
docrine hepatic metastasectomy are summarized in Table 2.
A 2009 Cochrane Database review of the published literature
available at that time did not identify any randomized trials
to compare surgical versus nonsurgical treatment of NET
metastases to the liver, nor “any quasirandomised studies,
cohort studies, or case-control studies that could inform
meaningfully,” but still concluded that surgery was appar-
ently the mainstay of survival-prolonging management [29].
The tendency of the neuroendocrine tumors to reappear is a
persistent problem [17] but should not create an attitude of
surgical nihilism. Recurrence does not preclude the potential
forinitialcytoreductiontooﬀersigniﬁcantgainsinsymptom
control and survival. The rates of recurrence seen at the site
of resection may actually be lower in NETs than with other
hepatic malignancies [6].
3. HepaticArtery Embolization
and Chemoembolization
Because liver metastases derive most of their blood supply
from the hepatic artery, local devascularization oﬀers a tar-
geted approach that takes advantage of neoplastic hyper-
vascularity, especially as healthy hepatocytes derive most of
their blood supply from the portal vein. Selective tumor
ischemia by occlusion of the hepatic artery, accomplished
either through “bland” embolization using only particles of
polyvinyl alcohol or through the augmented infusion of a
chemotherapeutic slurry (such as doxorubicin/mitomycin)
or microparticles [35], is an attractive strategy with which
to diminish the NET metastatic burden and improve quality
of life for patients who are not surgical candidates. The
infusions are accomplished via a catheter inserted under
ﬂuoroscopic guidance into the celiac or mesenteric arteries
and then advanced into the hepatic vasculature so that the
interventionalradiologistcanselectthedownstreamvascular
territory to be embolized.
Response rates after embolization vary between 50 and
96% from study to study, depending partly upon which
criteria of radiographic regression, symptom control, and/or
biochemical improvement are used [36–40]. Median dura-
tion of response extends up to 18 months [5]. Low- and
intermediate-grade neuroendocrine carcinomas are more
likely to show a durable response to hepatic artery emboliza-
tion (HAE) and chemoembolization (HACE), whereas the
proliferative rate of high-grade neoplasms will usually out-
pace regeneration of normal hepatocytes, increasing the like-
lihoodofrecurrenceandunfavorablyshiftingtheprocedure’s
risk:beneﬁt ratio [41]. It is inevitable that, in spite of careful
eﬀorts to limit obstruction exclusively to the lesion’s vascular
supply, some normal hepatic parenchyma will be aﬀected by
embolization of even very distal vessels, and the “postem-
bolization syndrome”—variably deﬁned as the constellation4 International Journal of Hepatology
Table 2: Summary of outcomes from resection of neuroendocrine liver metastases. OS: overall survival; PFS: progression-free survival.
First author,
publication year No. of surgical patients Median followup,
months Survival data Predictors of survival
Mayo, 2011 [30] 339 [66 with simultaneous
ablation] 26 Median OS: 123 months
5-year survival: 74%
Symptomatic high-volume [>25%
liver involved] disease beneﬁted most
from surgery (versus intra-arterial
therapy, P<. 001)
Saxena, 2011 [16] 74 [38 with simultaneous
cryoablation] 41 Median PFS: 23 months Worse PFS with R1 (versus R0)
pathologic margin status (P = .023)
Median OS: 95 months
Worse OS from higher grade (well
versus moderate versus poor
diﬀerentiation, P<. 001) and
extrahepatic disease (P = .021)
Karabulut, 2011 [31] 27 [excluding subsequent
liver transplants] 29 Median PFS: 15 months
Median OS: 190 months
Margin status did not aﬀect OS; in
outcomes analysis including RFA and
embolization, worse OS with male
gender (P = .04), dominant metastasis
>5cm(versus<3cm,P = .04),
extrahepatic disease (P = .03)
Glazer, 2010 [32]
172 [120 with small bowel
or pancreatic primaries; 18
had only RFA]
50
Median OS: 116 months
5-year survival: 77.4%
10-year survival: 50.4%
Increasing time interval from primary
resection to hepatic metastases
predicted for poorer survival (P = .01)
Sarmiento, 2003 [8] 170 [75 with complete
resection]
Not reported
(excluded <12
months followup)
Median OS: 81 months
5-year survival: 61%
10-year survival: 35%
No OS diﬀerence with or without
endocrinopathy (60% versus 61% at 5
years, P = .7 5 ) ,n oO Sd i ﬀerence
between carcinoid and islet cell (87
versus 66 months, P = .058)
Elias, 2003 [33] 47 [36 with concurrent
extrahepatic resection] 62
Median OS: 91 months
5-year survival: 71%
10-year survival: 35%
Worse DFS with incomplete surgery
( R 2v e r s u sR 1v e r s u sR 0 ,P = .003),
pancreatic origin (P = .01), bilateral
liver involvement (P = .01); no factor
predicted OS
Chen, 1998 [34]1 5 2 7
5-year survival: 73%
[versus 29% in 23 patients
with unresectable disease]
Median survival not reached in
resection group, but OS signiﬁcantly
longer than unresected (P = .003)
of elevated liver function tests, right upper quadrant pain,
nausea/vomiting, and fever—should be anticipated with
appropriate supportive care. A practice shift away from
common hepatic artery occlusion or simultaneous bilobar
treatment towards sequential, lateralized embolization of the
left or right hepatic artery has decreased the incidence of
fulminant hepatic failure after HAE and HACE [42, 43].
4. Radioembolization
Radioembolizationissimilarinprincipletochemoemboliza-
tionbutusesradioactivemicrospheresofytrrium-90(90Y)in
combination with embolic agents [44]. Again, the hypervas-
cularityofneuroendocrinemetastasesmakesthemamenable
to this approach, as high-energy beta-particles can be pref-
erentially delivered to heavily perfused tumors with relative
sparing of normal liver parenchyma [41]. Theraspheres
(MDS Nordion, Ottawa, ON, Canada) and SIR-Spheres
(SirtexMedicalLimited,NewSouthWales,Australia)referto
proprietaryradiopharmaceuticalsthatdiﬀerintherespective
composition (nonbiodegradable glass versus biodegradable
resin) and diameter (20–30µm versus 20–60µm) of their
microspheres [44]. An MD Anderson study of 8 patients
given SIR-Spheres for NETs (6 islet cell tumors, 2 carcinoids)
delivered a median ﬁrst radiation dose of 35.75mCi. All 8
patients had disease that had previously been treated with
HAE or HACE; the SIR-Spheres produced a partial response
in 1 patient and stable disease in 4 patients, but 3 patients
progressed [41]. The study provided proof of principle that
the intermixture of radioactive and nonradioactive embolic
agents does not preclude the possibility of response from
neuroendocrine hepatic metastases, and higher response
rates have been observed in other series; for instance, in
a single-institution study performed upon 34 patients with
nonresectable metastatic disease, King et al. described 50%
or greater symptomatic and radiographic responses, with an
18%rateofcompleteresponse onimaging, andameanover-
all survival of 29.4 months [45]. In the MD Anderson study,
postembolization sequelae were considered more tolerable
after radioembolization when compared to the after eﬀects
of HAE and HACE, but 3 patients developed abdominal painInternational Journal of Hepatology 5
after the ﬁrst 90Y treatment that then prevented them from
proceeding to a planned second treatment [41]. Another
important distinction from HAE and HACE is that radioem-
bolizationpatientsshouldundergopreproceduralevaluation
for hepatopulmonary shunts to ensure that no more than
20% of bloodﬂow is diverted to the lungs and to minimize
extrahepatic delivery of yttrium [44]. Circulatory reﬂux into
the gastroduodenal arteries also increases the risk of irra-
diation beyond target lesions in the liver. Pretherapeutic
technetium-99m-(99mTc-)labeledmacroaggregatedalbumin
(MAA)scanscanexcludetheseconditions[46].Patientswho
are deemed untreatable on the basis of unacceptably high
arteriohepatovenous shunting can actually have their shunts
occluded through the temporary inﬂation of balloons within
the hepatic veins, which may then enable radioembolization
to occur more safely [47]. The risk of radiation pneumonitis
and GI toxicity associated with radioembolization should be
balanced against the potential beneﬁt of the 90Yb e a d sa s
salvage therapy for unresectable liver disease, especially in
NET patients for whom carcinoid syndrome is signiﬁcantly
detrimental to their quality of life [48].
5. Hepatic Artery Infusion
Hepatic artery infusion involves placing a pump inside the
hepatic artery for the direct delivery of chemotherapeutic
agentstothedownstreamvascularterritories[44].Whilethis
specialized technique is most often applied to the treatment
of colorectal metastases, and even then only in tertiary
care centers, it has rarely been used in the management of
metastaticNETs,mostlyasanadjuncttochemoembolization
[49]. In a study by Christante et al., 77 patients with hepatic
neuroendocrine metastases who progressed despite treat-
ment with somatostatin analogues were treated either with
HAI then HACE (59 patients), or with HAI alone (18
patients). The infusion regimen consisted of four monthly
instillations of 5-ﬂuorouracil. The overall response rate,
measuring radiographic or symptomatic improvement, was
80%. Median progression-free survival was 19 months, with
all patients initiating HAI when their hepatic disease ﬁrst
enlarged during octreotide therapy. However, the median
disease-speciﬁc survival of 39 months was not clearly dif-
ferent from the outcomes of bland embolization or HACE
without HAI [49]. Outcomes from various trials of intra-
arterial therapy are reported in Table 3.
6. Thermal Ablation
Thermal ablative approaches to hepatic metastases rely on
the cytotoxic eﬀects of nonphysiologic temperatures that are
focally induced within the liver by carefully placed probes.
These instruments are designed to create extreme heat or
cold, either of which can result in cell death, within a con-
ﬁned range of surrounding tissue. Radiofrequency ablation
(RFA) and microwave ablation (MWA) are the most popular
methods for inducing heat-related cell death [55]. Cryoabla-
tion, in contrast, produces damaging temperatures far below
the freezing point of intracellular water. Ablation techniques
can be applied in the setting of inoperable disease, or, at
the surgeon’s discretion, as a complement to resection, for
example, to eradicate small foci of disease deep in the hep-
atic parenchyma with minimal disturbance to surrounding
tissues and optimal preservation of residual liver.
In RFA, high-frequency current courses through an elec-
trode, which is inserted in needle-like fashion into the target
lesion under ultrasound or CT guidance, through percuta-
neousorlaparoscopicapproaches,orduringlaparotomy[55,
56]. Heat is generated after a change in the direction of the
alternating current causes ionic vibration [57]. Intracellular
proteins will denature and lipid bilayers will melt after fewer
than two minutes above temperatures of 60◦C, and the cells
through which the radiofrequency electrical current passes
directly can reach temperatures above 100◦C, which boils
the tissue and creates water vapor [58]; lower temperatures
require longer exposure times, for example, eight minutes at
46◦C are needed to induce coagulative necrosis of malignant
cells through thrombosis of their microvasculature [58].
Beyond the zone of complete coagulation, tissue will be
partly destroyed in a spherical distribution up to 0.8cm in
diameter. A single electrode can induce cell death up to
1.6cm from the center of the tumor [59], and multiple elec-
t r o d e sc a nb ed e p l o y e di na na r r a yt oc r e a t eas p h e r i c a lb u r n
beyond 5cm in diameter [60]. Intraprocedural ultrasound
can almost immediately assess the size of the necrotic zone
to maximize the likelihood of adequate thermal damage to
the site of known metastasis, which should, in theory, lower
recurrence rates [61].
One of the largest prospective trials of RFA, which in-
cluded 54patients withunresectablehepaticmetastasesfrom
carcinoid or islet cell tumors (as well as 9 patients with
metastasesfrommedullarythyroidcarcinoma),andinwhich
ablation was performed laparoscopically under ultrasound
guidance, demonstrated a median survival of 3.9 years
following the ﬁrst ablation, and extrahepatic disease was not
a criterion for exclusion. In measuring the diameter of the
largest liver lesion targeted for ablation, 3 centimeters was
an important cutpoint for predicting survival, with patients
whosedominantlesionswereatorabovethisthresholdexpe-
riencing a median survival fewer than 3 years, whereas the
median survival for patients with dominant lesions smaller
than 3 centimeters had not been reached by the time the
studyconcluded.Over90%ofpatientsreportedpostablation
symptomatic improvement, and the median duration of
symptom control was 11 months. Male gender was also sig-
nificantly associated with poorer postablation survival, for
reasons that were unclear [62].
In an even larger study, Mulier et al. performed a meta-
analysis of 95 separate series describing the use of RFA in
the control of liver tumors. The pooled data allowed the
authors to examine the postablation outcomes of 5224
hepatic lesions of varying histologies. 11 of the 330 reported
neuroendocrine metastases demonstrated recurrence, with a
minimum follow-up period of 6 months, and this 3.3% rate
of recurrence for NETs was the lowest among the diﬀerent
categories of pathology, that is, versus hepatocellular carci-
noma and metastases from colon, breast, and unspeciﬁed6 International Journal of Hepatology
Table 3: Summary of outcomes for intraarterial therapy of neuroendocrine liver metastases. HAE: hepatic artery embolization; HACE:
hepatic artery chemoembolization; HAI: hepatic artery infusion; OS: overall survival.
First author,
publication year No. of embolized patients Survival data Comments
Paprottka, 2011 [50]4 2 [ 90Y radio-embolization] 40 of 42 patients alive with mean
followup of 16.2 months
36 of 38 symptomatic patients had
clinical improvement within 3 months
Dong, 2010 [51] 123 [HACE] Mean OS: 39.6 months 5-year OS: 36%
10-year OS: 20%
Baseline albumin <3.5g/dL was a
multivariate predictor for poorer OS
(P = .003)
Kennedy, 2008 [52] 148 [90Y radio-embolization] Median OS: 70 months No radiation-induced liver disease or
failure, even with retreatment
Christante, 2008 [49] 77 [18 HAI alone, 59 HAI +
HACE]
Median OS [HAI alone]: 26 months
Median OS [HAI + HACE]: 39 months
All 10 patients with nonfunctional
neoplasms and 15 of 16 patients with
islet cell neoplasms died within 5 years
Strosberg, 2006 [53] 84 [HAE] Median OS: 36 months Fewer symptoms in 44 of 55 patients
Gupta, 2005 [54] 123 [74 HAE, 49 HACE] Median OS [carcinoid]: 33.8 months
Median OS [islet cell]: 23.2 months
Male gender predicted worse OS
(P = .05) for carcinoid, bone mets
predicted worse OS for islet cell (P = .03)
primary tumors. Indeed, in univariate analysis, neuroen-
docrinehistologywasatumor-dependentfactorsigniﬁcantly
associated with a lower likelihood of local recurrence, along
with smaller size (<3cmversus3–5cmand>5cm), a non-
subcapsular(versussubcapsular)location,anddistancefrom
a major vessel. When these factors were subjected to mul-
tivariate analysis, however, only a small size of the ablated
lesion was signiﬁcantly associated with lower recurrence,
with Mulier and colleagues commenting that the minimum
postablationfollowupof6monthsmayhavebeenatooshort
intervalandthusunderestimatedtherecurrencerateinNETs
with a slower mean natural growth rate [63].
Microwaves are a nonionizing form of radiation that
causes extremely rapid oscillation of the water within tis-
sues, with dipolar reversals occurring a billion times per
second. Friction from the ﬂuctuation of intracellular water
molecules generates heat, which in turn leads to coagulative
necrosis [64]. The intratumoral temperatures of MWA are
consistently higher than can be achieved with RFA [65].
Also, as opposed to the mostly passive conduction of heat in
RFA, in which the “heat sink” eﬀect of relatively cool nearby
bloodﬂow can result in incomplete ablation of tumors close
tothelargerhepaticvessels,theMWAmethodinvolvesactive
heating that may be more appropriate for targeting tumor
sites next to major hepatic vasculature [55, 64]. As in RFA,
a probe is placed into the target lesion under radiographic
guidance or during open surgery. Multiple lesions can be
ablated during the same procedure. The clinical experience
with MWA has, to date, mostly involved treatment of hepa-
tocellular carcinoma, but neuroendocrine tumors have been
included in some series. Martin et al. described that, of 100
patients undergoing MWA for primary or secondary hepatic
tumors at their institution during a 5-year period, 11 had
neuroendocrine pathology. A 90% success rate for com-
plete ablation was reported for carcinoid tumors, with no
recurrences at the ablation sites. The authors noted that
the multiplicity of lesions in metastatic carcinoid, as well
as the intraprocedural diﬃculties of locating all the tumors
seen on preprocedural CT, prevented achievement of a 100%
complete ablation rate [65]. It is important to recognize that
the majority of these patients had MWA performed under
ultrasound guidance during open surgery, that is, concomi-
tant hepatectomy and/or extrahepatic metastasectomy [65].
There is still a paucity of data comparing MWA (especially
performed percutaneously) to RFA for management of NETs
in the liver.
Cryoablation is the most mature thermoablation tech-
nique, having ﬁrst been proposed in 1851 [66]. Cell viability
is decreased at low temperatures, depending partly on the
rate of cooling and the spatial relationship to ice forma-
tion around the cryoablation probe [67]. While cryogenic
temperatures can both preserve and destroy tissue [68], the
primary determinant of cell death is the depth of the lowest
obtained tissue temperature, which should be −50◦Ct o
achievenecrosisinneoplastictissue[69].Inadditiontonear-
immediate mechanical injury caused during a freeze by ice
crystals disrupting their membranes and organelles, cells can
die during the thaw and postthaw periods due to disrupted
vascular supply or due to cold-activated endonucleases trig-
gering an apoptotic response [68]. However, malignant
cells may be more resistant to lethal damage from freezing
compared to hyperthermia [58] ,a n ds o m es t u d i e sh a v e
reported higher complication and recurrence rates when
cryoablation is compared against heat-based therapies [55].
Seifert et al. described a series of 13 patients with NETs who
underwent hepatic cryotherapy; in each case, the cryoprobes
were inserted under ultrasound guidance, and freezing was
monitored until the ball of ice extended beyond the tumor
for1cminalldirections.12of13patientshadcompleteabla-
tion of all visible tumors, with 2 recurrences at the ablation
sites and 12 survivors at 1 year of followup. All 7 patients
who had hormonally related symptoms prior to cryotherapy
experienced palliative beneﬁt. 2 patients developed a post-
procedural coagulopathy requiring intra-abdominal packingInternational Journal of Hepatology 7
Table 4:Summaryofoutcomesforablationofneuroendocrinelivermetastases.DFS:disease-freesurvival;MWA:microwaveablation;NET:
neuroendocrine tumor; OS: overall survival; PFS: progression-free survival; RFA: radiofrequency ablation.
Author, publication
year No. of ablated patients Median followup,
months Survival data Comments
Karabulut, 2011 [31]6 8 [ R F A ] 2 2 Median PFS: 10.5 months
Median OS: 73 months
No signiﬁcant overall survival
diﬀerence between RFA and resection
Akylidiz, 2010 [71]
89 [RFA; 78 with NETs
of GI origin, 11
medullary thyroid
cancer]
30 Median DFS: 15.6 months
Median OS: 72 months
Liver tumor volume (>76cc versus
<30cc, P = .04), symptoms (present
versus absent, P = .04), extrahepatic
disease (P = .02)
Martin, 2010 [65]
11 [MWA; 7 with
concomitant
hepatectomy; 6 with
concomitant
extrahepatic resection]
36 Median DFS: 8 months
Median OS: 18 months Zero recurrences at ablation site
Mazzaglia, 2007 [62]
63 [RFA; 24 with
extrahepatic disease at
time of 1st ablation; 9
patients with
medullary thyroid
cancer]
34
Median OS: 47 months
after 1st RFA
5-year survival: 48%
Male gender [3x mortality risk of
female] (P = .04), largest tumor >3cm
(P = .03)
Seifert, 1998 [70] 13 [cryoablation] 13.5
12 patients alive at the end
of followup
(up to 103 months)
All 7 symptomatic patients had
subjective improvement
Shapiro, 1998 [72] 5 [cryoablation] 30 1-year survival: 60% 2-year
survival: 40%
All 5 patients had relief of carcinoid
syndrome
and the transfusion of clotting factors. The authors had not
observedsimilarbleedingcomplicationswhenapplyingtheir
cryosurgical techniques to patients with hepatocellular car-
cinoma and speculated that the necrosing carcinoid tumors
were releasing substances into circulation that disrupted the
coagulation cascade. All patients demonstrated thrombo-
cytopenia two days after the procedure [70]. In a larger
series by Bilchik et al. of 17 patients undergoing hepatic
cryosurgery for NETs, all patients demonstrated a transient
coagulopathy, requiring transfusion of either platelets or
fresh frozen plasma (with an average infusion of 4 units per
procedure) [66].
Outcomes for various studies of ablative therapies in the
setting of NETs metastatic to the liver are summarized in
Table 4.
7. Alcohol Ablation
Ultrasound-guided injection of ethanol, otherwise known as
percutaneous alcohol injection (PAI), into neuroendocrine
metastases has been described in multiple series [75, 76],
none of which were histologically exclusive to NETs. A 1994
report by Giovannini and Sietz included 5 NETs among
40 patients with various pathologies undergoing PAI, and
complete necrosis rates in carcinoid tumors were inferior to
theresponsesseenincolorectalmetastases[73].Nonetheless,
PAI could be an advantageous technique over RFA when
tumors are located next to large vessels that would be vulner-
able to the “heat sink” eﬀect, or in proximity to central bile
ducts that tend to stricture in response to heat [5]. Lesions
chosen for ethanol ablation are necessarily less than 5cm in
diameter and the cubic volume of alcohol injected requires
modeling the target tumor as a sphere, but these estimations
are more likely to be accurate when the radius is shorter, and
very small metastases can be ablated with minimal collateral
damage to the surrounding liver [5]. In a smaller study by
Livraghi et al., in which 2 of 14 patients with liver metastases
had neuroendocrine carcinoma, the patients demonstrated
a complete response after ablation of 4 lesions smaller than
3.1cm [74]. Thus, PAI is best used not as monotherapy
but rather as an adjunct to newer ablative techniques when
approaching tiny or inauspiciously located metastases [5,
75]. All of the ablation methods are summarized in Table 5.
8. LiverTransplantation
On its list of indications for orthotopic liver transplantation,
the United Network for Organ Sharing (UNOS) includes
“metastatic neuroendocrine tumors (carcinoid tumors,
APUDomas, gastrinomas, glucagonomas) in persons with
severe symptoms and with metastases restricted to the liver,
who are unresponsive to adjuvant therapy after aggressive
surgical resection including excision of the primary lesion
andreductionofhepaticmetastases.”However,thepublished
experience with liver transplantation for NETs remains
limited, and fewer than 300 unique cases are described in the
literature [80]. A meta-analysis of 20 studies encompassing
89 patients transplanted for metastatic pancreatic NETs8 International Journal of Hepatology
Table 5: Summary of liver-directed ablation modalities.
Ablation technique Mechanism of tumor injury Maximum size of target lesion Comments/caveats
RFA Heat 1.6cm: single electrode 5cm: array Prone to heat sink from adjacent vessel,
↓ control for lesions >4cm
MWA Heat 2cm: single needle 4cm: parallel needles Less prone to heat sink, but fewer
supportive data than RFA
Cryoablation Cold 4cm: single needle 6cm: multiple needles
↓ control for lesions >4cm,riskof
↓ platelets and coagulopathy
Alcohol Toxic 4cm Adjunctive only
Table 6: Summary of outcomes for liver transplantation for neuroendocrine metastases. OS: overall survival.
Author, publication
year
No. of liver transplant (LT)
patients Survival data Predictors of survival
Gedaly, 2011 [76] 150 [13 receiving another
organ at time of LT]
49% 5-year survival [excluding
multiple organ transplants]
Regardless of age, improved survival (>60%
at 5 years) for patients waiting more than 2
months for transplant (P = .005)
Mathe, 2011 [77] 89 44% 5-year survival
Worse survival with recipient age >55
(P = .0242) and simultaneous LT-pancreas
resection (P = .0132)
Rosenau, 2002 [78]1 9 80% 5-year survival
50% 10-year survival
Ki-67 <5 %a n dn o r m a lE - c a d h e r i n
expression had 100% 7-year survival (versus
0% when Ki-67% >5% or aberrant
E-cadherin expression, P = .007)
Le Treut, 2008 [79] 85 [34 with concurrent
extrahepatic resection] Median OS: 56 months
Exenteration (P = .0034), a
duodenopancreatic primary (P = .0018),
and hepatomegaly (P = .0157), all predicted
f o rp o o r e rs u r v i v a l
Neuroendocrine tumor with
suspected liver metastasis
Histologic assessment of tumor:
differentiation, Ki-67, necrosis
Radiographic assessment of intra-and
extrahepatic disease
Intrahepatic-MRI > CT Extrahepatic-
nuclear medicine study
(18FF-DOPA PET > octreotide
scintigraphy for carcinoid)
Multidisciplinary evaluation withsurgery and interventional radiology
Clearly resectable Borderline resectable Unresectable
Thermal ablation Radioembolization,
HAE, HACE
Consider transplantation if
age <55 without need for
concurrent major
resection of extrahepatic
disease
Remnant liver volume >30%?
Yes:
proceed to
metastasectomy
Can be
concurrent
No:
consider portal vein
embolization
Figure 1: Liver-directed treatment algorithm for neuroendocrine hepatic metastases.International Journal of Hepatology 9
reported cumulative 1-, 3-, and 5-year survival rates of 71%,
55%, and 44%, respectively. Recurrence-free survivals were
84%, 47%, and 47% at the same respective time points. If
patients were 55 years old or younger and were not undergo-
ing simultaneous pancreatic resection, then their predicted
5-year survival was 61%. Conversely, a 0% 5-year survival
rate was prognosticated for patients older than 55 who were
undergoing resection of the primary pancreatic lesion at the
same time as transplantation [77]. The largest single-center
experience with liver transplantation for NETs reports a 10-
year survival rate of 50% among 19 patients. 12 patients
recurred, within 2 weeks to 48 months from the date of
transplant. 3 patients had recurrence-free survivals beyond 8
years. 7-year survival was 100% in the 5 patients with Ki67 in
less than 5% of their tumor cells and normal expression of E-
cadherin, that is, positive membrane and absent cytoplasmic
staining [78]. A multicenter French study pooled 85 cases
of liver transplantation performed for NETs between 1989
and 2005. 34 of the patients underwent concurrent resection
of extrahepatic disease, which in 7 cases required upper
abdominal exenteration (resection of the pancreas, spleen,
stomach, and duodenum, with 3 patients receiving en bloc
composite liver-duodenum-pancreas grafts). Concomitant
exenteration had the strongest association with death in
multivariate analysis (RR: 3.72, 95% CI: 1.54–8.95, P =
.0034), with 0% 3-year survival and a median survival of
1.5 months, whereas the median survival among all patients
was 56 months. Excluding exenteration, the most important
prognostic factors were a duodenopancreatic location of the
primary tumor and hepatomegaly (≥120% standard liver
volume in the explanted organ); the 23 patients with both of
these attributes had a 12% 5-year survival versus 68% 5-year
survival among the 55 patients with only one or neither of
thesefactors[79].Clearly,thedecisiontotransplantapatient
with neuroendocrine carcinoma metastatic to the liver
requirescarefulconsiderationofnumerousclinicopathologic
variables, and mortality is higher in older individuals requir-
ing concurrent disease resections. Outcomes for studies of
liver transplantation for involvement by metastatic NETs are
summarized in Table 6.
9. Conclusion
The unique tumor biology of neuroendocrine carcinomas
presents disease-speciﬁc challenges when hepatic metastases
occur [81], but some characteristics of these neoplasms lend
themselves to management with liver-directed therapy. Med-
ical oncologists should work in multidisciplinary fashion
with surgeons and interventional radiologists to assess the
potential utility of these organ-focused techniques in series
with exciting advances in systemic management of NETs,
such as peptide receptor radionuclide therapy (PRRT) [82]
and promising chemotherapeutic agents like sunitinib [83]
and everolimus [84]. It is beyond the scope of this review
of liver-directed therapy to adequately address PRRT and
chemotherapy, but, in conclusion, we propose the algorithm
shownin(Figure 1)forapproachingneuroendocrinehepatic
metastases.
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